Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22360123 | 0.87 | CYP2A6 (0.36) | DYRK1ASETDB1CYP2A6PDCD1CD274 | |
| SCHEMBL22051064 | 0.85 | PDCD1 (0.37) | DYRK1ASETDB1PDCD1CD274ALDH1A1 | |
| SCHEMBL2460353 | 0.81 | DYRK1A (0.40) | DYRK1ASETDB1CYP2A6PDCD1CD274 | |
| SCHEMBL2460718 | 0.80 | CYP1A2 (0.43) | DYRK1APIN1MAPTMEN1KMT2A | |
| SCHEMBL2460419 | 0.80 | GABRA1 (0.46) | DYRK1APIN1ALDH1A1MAPTALB | |
| SCHEMBL22360089 | 0.79 | ABCC9 (0.30) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL22360107 | 0.79 | ABCC9 (0.30) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2463716 | 0.78 | GAA (0.48) | KDM4EMAPTKMT2AGAALMNA | |
| SCHEMBL29952696 | 0.77 | CYP2A6 (0.44) | DYRK1ASETDB1CYP2A6PIN1ALDH1A1 | |
| SCHEMBL1859259 | 0.77 | CYP2A6 (0.44) | DYRK1ASETDB1CYP2A6PIN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| EP-2029591-B1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2029591-B1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2007140934-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305052-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | QDPR, NQO1, NAT1 | DYRK1A 1649/4885SETDB1 4820/4885CYP2A6 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.